Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

Johnson & Johnson JNJ will begin the earnings season for the drug & biotech sector when it reports its second-quarter 2025 results on July 16. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.79 billion and $2.66 per share, respectively. The Zacks Consensus Estimate for J&J’s...